Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure

Last updated: March 4, 2013
Sponsor: University of Cincinnati
Overall Status: Terminated

Phase

3

Condition

Traumatic Brain Injury

Memory Loss

Neurologic Disorders

Treatment

N/A

Clinical Study ID

NCT01111682
Shutter-2010-01
  • Ages 18-70
  • All Genders

Study Summary

This study examines the role of osmotic agents in controlling brain swelling in brain injured individuals. Two osmotic agents -- mannitol and hypertonic saline -- are in common use, and they will be compared in the context of a randomized clinical trial. The goal is to determine if these agent differ in their ability to control episodes of brain swelling.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • closed traumatic brain injury

  • either (i) GCS score 3-8 (inclusive), or (ii) GCS motor score of 5 or less ANDabnormal admission CT scan showing intracranial pathology

  • hemodynamically stable with systolic blood pressure greater than 90 mmHg

  • at least 1 reactive pupil

  • age between 18y and 70y (inclusive)

  • INR less than 1.5

Exclusion

Exclusion Criteria:

  • actively on hypertonic saline or mannitol

  • hypernatremia (>145 meq/L)

  • anuric or with creatinine greater than or equal to 2.5

  • known seizure disorder

  • penetrating head trauma

  • suspected anoxic events

  • history of, or CT confirmation of, previous brain injury

  • any injury that, in the opinion of the Principal Investigator, has a high likelihoodof death with the first 72 hours post-injury

  • any treatment, condition, or injury that contraindicates treatment with hypertonicsaline

Study Design

Total Participants: 5
Study Start date:
April 01, 2010
Estimated Completion Date:
November 30, 2010

Study Description

This single-center, randomized, open label trial will compare (i) 0.9% normal saline infusion and boluses of mannitol (control group) with (ii) 3% hypertonic saline, with intermittent boluses as needed, to treat elevated intracranial pressure (ICP) following severe traumatic brain injury.

Patients will be randomized to one of the two study arms following placement of an ICP monitor. Raised ICP will be defined as an ICP greater than 20 mmHG for 20 minutes or longer. In the event of such an event, the appropriate treatment will be administered.

The primary endpoint will be success in ICP control, operationalized as the proportion of time during which ICP is less than or equal to 20 mmHg during the first 120 hours following initiation of monitoring. Secondary endpoints include therapy intensity level, incidence of pre-determined severe adverse events, and long-term outcomes measured at 3 and 6 months post-injury.

Connect with a study center

  • University Hospital

    Cincinnati, Ohio 45267
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.